John Brownlee

John Brownlee was a former paratrooper and Army Reserve JAG Corps captain whose effort to prosecute Purdue Pharma made him a central figure in the federal response to OxyContin’s marketing. Brash, media-conscious, and intent on pursuing high-stakes cases, he began investigating the company in 2003 and kept the inquiry secret until 2005. The case he assembled culminated in Purdue’s 2007 guilty plea and a $600 million settlement, a major legal reckoning built from years of document review, patient and family evidence, and persistence against a powerful corporate defense.

Identity and Ambition

At thirty-six, Brownlee was a young U.S. attorney in western Virginia with a military legal background and an appetite for public-facing prosecution. He cultivated a forceful image: ruddy-complexioned and boyish in appearance, but hard-charging in manner. He also traveled with a portable podium whose legs folded out, a practical emblem of how readily he brought his cases before the press. His prosecutorial credo was that a lawyer who never lost was probably avoiding the hardest cases.

Ambition formed part of the picture. Brownlee planned to seek elected office and later ran for Virginia attorney general in 2008, the year after the Purdue case closed; he yielded the nomination to Ken Cuccinelli in 2009. Longtime reporter Laurence Hammack recalled that Brownlee may have regarded a prosecution of Purdue as a route to national attention. That possible self-interest did not erase the underlying stakes: OxyContin abuse was spreading nationally, and, as Hammack observed, no other prosecutor had taken the company on.

Setbacks and the Decision to Pursue Purdue

Before Purdue, Brownlee had endured a series of conspicuous setbacks. A wrongful-death prosecution involving a Roanoke pain specialist ended in an acquittal, a hung jury, and dismissal, while the aggressive conduct surrounding the case drew criticism. A separate high-profile prosecution also ended with two hung juries. These outcomes strengthened Brownlee’s need for a significant legal success, but they also help explain the forceful style that made him controversial. A later retrial of the physician resulted in convictions for racketeering, health care fraud, and marijuana distribution, and the physician lost his medical license.

Brownlee began the Purdue investigation almost immediately after becoming U.S. attorney, but held it out of public view until 2005. He had read Barry Meier’s Pain Killer and knew Purdue had tried to challenge Meier’s position at the newspaper after the book appeared. Purdue lawyer Howard Udell had argued that Meier’s book gave him a financial interest in continued coverage and sought to have him removed from the subject. Meier later described the effort as an attempt to suppress reporting. Brownlee, however, could study the book’s footnotes even while Meier’s coverage of Purdue was curtailed.

That research became part of a much larger evidentiary effort. Brownlee relied on Gregg Wood, a fraud investigator in his office, who had long circulated regular email compilations of OxyContin-related news and overdose statistics to law-enforcement officials, prosecutors, and others. Wood urged recipients to send him local information; Art Van Zee nicknamed the compilations the Wood Reports. Brownlee’s office was secretly logging millions of records in spreadsheets, with one employee assigned to catalog documents. Files from Fayne McCauley’s case, including sales-representative call notes and depositions, were added to the material. Together, these records reinforced the prosecutors’ belief that Purdue had knowingly concealed the drug’s addictiveness.

Building the Case and Resisting Pressure

When news of the federal grand-jury investigation broke in 2005, some parents involved in Relatives Against Purdue Pharma feared that the company expected to overwhelm local lawyers. Purdue had won many earlier legal battles, and the federal case presented a difficult question: prosecutors were not required to prove that Purdue itself caused particular overdoses or cases of addiction, but to establish criminal misbranding. The legal boundary was not simple. Brownlee assigned career prosecutors Randy Ramseyer and Rick Mountcastle to lead the investigation. They worked from the district’s satellite office in Abingdon, closer to the coalfields, while Brownlee brought in prosecutors from neighboring jurisdictions to handle other work.

Purdue mounted an intensive effort to influence the investigation and negotiations. Rudy Giuliani made repeated calls on the company’s behalf, and Brownlee prepared for their first meeting by reading Giuliani’s book. In 2005, after Purdue lawyers complained to Deputy Attorney General James Comey about Brownlee’s investigative tactics, Comey contacted him with concerns. Brownlee drove to Washington to explain his strategy and was told to return to Virginia and continue the case. He regarded the prosecution as winnable even for a small office: determined prosecutors working from Abingdon could take on one of the state’s largest cases.

The pressure escalated as plea negotiations approached their deadline. In October 2006, the night before the agreement was due to expire, a senior Justice Department official called Brownlee at home, at a Purdue lawyer’s request, to seek an extension. By then Brownlee had spent years resisting the company’s efforts to delay or reshape the case. Purdue accepted the plea agreement later that night rather than risk more serious charges or a trial in western Virginia, where the drug’s effects had become widely known.

Eight days after accepting the agreement, Brownlee saw his name on a list of U.S. attorneys slated for dismissal, alongside four others. He was not fired, but the episode intensified criticism of Attorney General Alberto Gonzales and raised concerns about political interference in U.S. attorney offices. The involvement of Purdue’s defense lawyer in seeking more time from the Justice Department also illustrated how far the company’s influence reached. Brownlee later addressed the attempted influence in a Senate hearing about the case.

Settlement and Significance

In May 2007, Brownlee announced the settlement in the atrium of a downtown Roanoke office building. Purdue agreed to resolve federal criminal and civil misbranding charges, pay $600 million in fines, and admit that for six years it had fraudulently marketed OxyContin as less prone to abuse and as having fewer narcotic side effects than instant-release versions. The company’s felony admission concerned its marketing claims, not a finding that it had directly caused individual overdoses. Its top executives, Paul Goldenheim, Michael Friedman, and Howard Udell, agreed to plead guilty to misdemeanor versions of the offense; $34.5 million in penalties attributed to them would be paid by the firm on their behalf.

The fine represented about 90 percent of Purdue’s profits from OxyContin’s launch in 1996 through 2001, when the company dropped insert language asserting that the drug’s timed-release mechanism could reduce abuse liability. It was the eleventh-largest fine paid by a pharmaceutical company in the Justice Department’s history. The agreement did not require the executives to serve jail time. A sentencing hearing in Abingdon was scheduled for July, where grieving parents, including people associated with Relatives Against Purdue Pharma, were invited to describe the drug’s effects in court; the judge still had to approve the agreement and determine probation and community-service terms.

Brownlee’s case converted years of dispersed warnings, investigative records, and family testimony into a federal admission of criminal misbranding. Its achievement and limit were inseparable: the company and executives faced substantial financial penalties and formal guilty pleas, but the executives would not be imprisoned under the agreement. For Brownlee, the prosecution was both a high-profile legal victory and an example of how a small, determined team could withstand corporate and political pressure long enough to secure one.